TherapeuticsMD (TXMD) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
TherapeuticsMD (TXMD) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 122.18% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -33.32% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 63.07% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -11.73% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 243.47% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -13.38% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 107.90% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 75.58% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 104.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 104.46% |
| Mar 31, 2026 | 35.05% |
| Dec 31, 2025 | 2,105.88% |
| Sep 30, 2025 | 1,507.04% |
| Jun 30, 2025 | -73.78% |
| Mar 31, 2025 | 405.24% |
| Dec 31, 2024 | 100.34% |
| Sep 30, 2024 | 98.82% |
| Jun 30, 2024 | 142.84% |
| Mar 31, 2024 | 97.37% |
| Dec 31, 2023 | -116.40% |
| Sep 30, 2023 | -134.03% |
| Jun 30, 2023 | 83.63% |
| Mar 31, 2023 | 51.31% |
| Dec 31, 2022 | -37.01% |
| Sep 30, 2022 | 146.35% |
| Jun 30, 2022 | 21.90% |
| Mar 31, 2022 | 53.43% |
| Dec 31, 2021 | 258.12% |
| Sep 30, 2021 | -12.26% |